Roivant Sciences Stock Performance
| ROIV Stock | USD 10.66 0.24 2.30% |
The company holds a Beta of 0.25, which implies not very significant fluctuations relative to the market. As returns on the market increase, Roivant Sciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Roivant Sciences is expected to be smaller as well. At this point, Roivant Sciences has a negative expected return of -0.21%. Please make sure to check Roivant Sciences' jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Roivant Sciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Roivant Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's forward indicators remain fairly stable which may send shares a bit higher in April 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 1.7 B |
Roivant |
Roivant Sciences Relative Risk vs. Return Landscape
If you would invest 1,215 in Roivant Sciences on December 17, 2024 and sell it today you would lose (158.00) from holding Roivant Sciences or give up 13.0% of portfolio value over 90 days. Roivant Sciences is currently does not generate positive expected returns and assumes 1.9615% risk (volatility on return distribution) over the 90 days horizon. In different words, 17% of stocks are less volatile than Roivant, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Roivant Sciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Roivant Sciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Roivant Sciences, and traders can use it to determine the average amount a Roivant Sciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1066
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ROIV |
Estimated Market Risk
| 1.96 actual daily | 17 83% of assets are more volatile |
Expected Return
| -0.21 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Roivant Sciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Roivant Sciences by adding Roivant Sciences to a well-diversified portfolio.
Roivant Sciences Fundamentals Growth
Roivant Stock prices reflect investors' perceptions of the future prospects and financial health of Roivant Sciences, and Roivant Sciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Roivant Stock performance.
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.95) % | ||||
| Operating Margin | (29.22) % | ||||
| Current Valuation | 2.57 B | ||||
| Shares Outstanding | 713.55 M | ||||
| Price To Book | 1.47 X | ||||
| Price To Sales | 62.05 X | ||||
| Revenue | 124.8 M | ||||
| EBITDA | 4.31 B | ||||
| Cash And Equivalents | 1.94 B | ||||
| Cash Per Share | 2.76 X | ||||
| Total Debt | 499.75 M | ||||
| Debt To Equity | 0.28 % | ||||
| Book Value Per Share | 7.21 X | ||||
| Cash Flow From Operations | (765.27 M) | ||||
| Earnings Per Share | (1.00) X | ||||
| Total Asset | 7.22 B | ||||
| Retained Earnings | 576.17 M | ||||
About Roivant Sciences Performance
Evaluating Roivant Sciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Roivant Sciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Roivant Sciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company was founded in 2014 and is based in London, the United Kingdom. Roivant Sciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 863 people.Things to note about Roivant Sciences performance evaluation
Checking the ongoing alerts about Roivant Sciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Roivant Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Roivant Sciences generated a negative expected return over the last 90 days | |
| Roivant Sciences currently holds about 1.94 B in cash with (765.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.76. | |
| Over 80.0% of the company shares are owned by institutional investors |
- Analyzing Roivant Sciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Roivant Sciences' stock is overvalued or undervalued compared to its peers.
- Examining Roivant Sciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Roivant Sciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Roivant Sciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Roivant Sciences' stock. These opinions can provide insight into Roivant Sciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Roivant Stock Analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.